Diabetes Obes Metab: Effects of Exenatide and Dapagliflozin Monotherapy or Combination Therapy on Renal Function Markers in Obesity Patients with Type 2 Diabetes twice a day

Purpose: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used to improve blood sugar control, induce weight loss, and lower blood pressure in patients with type 2 diabetes.
Sugar medicine
.

In addition, SGLT2 inhibitors have been specifically studied to prove that they can reduce the risk of renal failure in patients with chronic kidney disease

Hypoglycemic drugs that improve blood sugar control, induce weight loss, and lower blood pressure in patients with type 2 diabetes reduce the risk of renal failure in patients with chronic kidney disease GLP-1RAs can also delay the progression of decreased renal function in patients with type 2 diabetes

Methods: In the secondary analysis of the weight reduction trial, we recruited 66 obese patients with type 2 diabetes for a 16-week randomized, double-blind, placebo-controlled clinical trial.
And a clinical follow-up will be carried out after 16 weeks
.

Participants collected 24-hour urine samples after baseline, 1.

Results: At week 16, compared with baseline, the average change in UACR in the exenatide group was 39.
6% (95% CI 58.
6, 11.
9, P=0.
001), and the average change in UACR in the dapagliflozin group was 18.
1% ( 95% CI 43.
1, 18.
0, P=0.
278), the average change in UACR in the exenatide group was 15.
6% (95% CI 41.
4, 21.
6, P=0.
357), and the average change in UACR in the placebo group was 11.
0% (95% CI 39.
8, 31.
5, P=0.
552)
.

Compared with placebo, the difference in UACR at week 16 in the exenatide-dapagliflozin group was 32.

^{2 2}

Table Baseline characteristics of subjects

Table Baseline characteristics of subjects

Figure taking placebo (red, n=14), exenatide (grey, n=16), dapagliflozin (light blue, n=16) and exenatide-dapagliflozin (dark blue) , N=16) Changes in renal function after 16 weeks
.

A, changes in urine albumin: creatinine ratio (UACR;%)

Figure taking placebo (red, n=14), exenatide (grey, n=16), dapagliflozin (light blue, n=16) and exenatide-dapagliflozin (dark blue) , N=16) Changes in renal function after 16 weeks

This study shows that, compared with monotherapy or placebo, the combination of dapagliflozin and exenatide may have a synergistic effect on renal function indicators in obese patients with type 2 diabetes

van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG,et al.

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial in this message